An interventional study of My Voice in Advance Care Planning and Heart Failure, sponsored by Duke-NUS Graduate Medical School. Active, not recruiting at 1 site in Singapore. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by Duke-NUS Graduate Medical School · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Heart Failure with a site in Singapore — 6 open to participants now, 14 under way, 2 of them phase 3. Heart Failure · Singapore.
Among the 62 studies in Heart Failure with a site in Singapore, this one is the 26th largest by planned enrollment of the 46 interventional ones that give a count, is one of 5 that started in 2024, is one of 17 with no phase, reaches primary completion later than 6 of the 13 other live ones, and was the 55th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →6 of the 62 studies in Heart Failure with a site in Singapore are open now. Recruiting first, the newest first:
Abbott Medical Devices · Sites in Singapore, Brazil, France and 6 more countries
Ages 18+
National Heart Centre Singapore · Sites in Singapore
Ages 21–99 · Healthy volunteers
National Cancer Centre, Singapore · Sites in Singapore
Ages 21–99
Merck Sharp & Dohme LLC · Sites in Singapore, United States, Belgium and 27 more countries
Ages 29 days–17 yrs
National University Heart Centre, Singapore · Sites in Singapore
Ages 18+
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 17 · Phase 4 4
First in 2006; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 244 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 310 across the 46 interventional studies, 678 across the 16 observational. Of the 45 that completed or were terminated, 27 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 62 have an industry lead sponsor. The 10 most frequent:
Duke-NUS Graduate Medical School is the lead sponsor of 63 studies on the registry; 6 are open to participants now.
Duke-NUS Graduate Medical School has 3 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
3 of the studies in Heart Failure with a site in Singapore that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
| NCT06090734Duke-NUS Graduate Medical SchoolDevelopment and Evaluation of 'My Voice': A Randomized Controlled Trial | 2027-03 |
| NCT07217392Abbott Medical DevicesLeft Bundle Branch Area Pacing (LBBAP) PMCF Study | 2027-04-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 62 studies in Heart Failure with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims to develop and evaluate a web-based interactive platform (called 'My Voice') that helps to educate patients with heart failure and their caregivers about heart failure, identify their goals for end-of-life care, and share these with their caregivers and doctors.
The research study consists of 3 phases:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- The inclusion criteria for patients are
The inclusion criteria for caregivers are
Exclusion criteria for caregivers are:
a) domestic helper
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention arm patients will complete the patient version of 'My Voice' at least once every 3 months for 1 year or until they pass away (whichever is earlier). Caregivers of patients in the intervention arm will complete the caregiver version of 'My Voice' at least once every 3 months for 1 year (or until the patient passes away, whichever is earlier).
Other: My Voice
Control arm patients and caregivers will receive usual care.
The web intervention educates patients about their illness and supports them to make their own Advance Care Planning decisions, update these decisions frequently as their clinical condition changes, and to make the ACP process easier and more accessible. The intervention aims to shift implementation of ACP from a provider-led one-time model to a patient-led dynamic model.
Proportion of patients who have ACP discussions with their treating doctor at least once during the study period
will be assessed from medical records and survey
Time frame: 1 year from data collection
Proportion of patients who have ACP discussions with their caregivers
will be assessed from the survey
Time frame: 1 year from data collection
Proportion of patients who prefer life-extending treatments
will be assessed from the survey
Time frame: 1 year from data collection
Proportion of patients with psychological distress
will be assessed from the survey
Time frame: 1 year from data collection
Peace and acceptance scores
will be assessed from the survey
Time frame: 1 year from data collection
Proportion of patients having decision maker
will be assessed from the survey
Time frame: 1 year from data collection
Plan to share: No
Started Mar 2024 (actual). Primary completion is estimated for Mar 2027, 36 months after the start.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 36 months is above that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Duke-NUS Graduate Medical School